MHGTMDA: molecular heterogeneous graph transformer based on biological entity graph for miRNA-disease associations prediction

IF 6.5 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Molecular Therapy. Nucleic Acids Pub Date : 2024-02-05 DOI:10.1016/j.omtn.2024.102139
Haitao Zou, Boya Ji, Meng Zhang, Fen Liu, Xiaolan Xie, Shaoliang Peng
{"title":"MHGTMDA: molecular heterogeneous graph transformer based on biological entity graph for miRNA-disease associations prediction","authors":"Haitao Zou, Boya Ji, Meng Zhang, Fen Liu, Xiaolan Xie, Shaoliang Peng","doi":"10.1016/j.omtn.2024.102139","DOIUrl":null,"url":null,"abstract":"<p>MicroRNAs (miRNAs) play a crucial role in the prevention, prognosis, diagnosis, and treatment of complex diseases. Existing computational methods primarily focus on biologically relevant molecules directly associated with miRNA or disease, overlooking the fact that the human body is a highly complex system where miRNA or disease may indirectly correlate with various types of biomolecules. To address this, we propose a novel prediction model named MHGTMDA (miRNA and disease association prediction using Heterogeneous Graph Transformer based on Molecular Heterogeneous Graph). MHGTMDA integrates biological entity relationships of eight biomolecules, constructing a relatively comprehensive heterogeneous biological entity graph. MHGTMDA serves as a powerful molecular heterogeneity map transformer, capturing structural elements and properties of miRNAs and diseases, revealing potential associations. In a 5-fold cross-validation study, MHGTMDA achieved an Area Under the Receiver Operating Characteristic Curve (AUC) of 0.9569, surpassing state-of-the-art methods by at least 3%. Feature ablation experiments suggest that considering features among multiple biomolecules is more effective in uncovering miRNA-disease correlations. Furthermore, we conducted differential expression analyses on breast cancer and lung cancer, using MHGTMDA to further validate differentially expressed miRNAs. The results demonstrate MHGTMDA’s capability to identify novel MDAs. MHGTMDA is free and available at <span>https://github.com/zht-code/HGTMDA.git</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"8px\" viewbox=\"0 0 8 8\" width=\"8px\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg>.</p>","PeriodicalId":18821,"journal":{"name":"Molecular Therapy. Nucleic Acids","volume":null,"pages":null},"PeriodicalIF":6.5000,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Nucleic Acids","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtn.2024.102139","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

MicroRNAs (miRNAs) play a crucial role in the prevention, prognosis, diagnosis, and treatment of complex diseases. Existing computational methods primarily focus on biologically relevant molecules directly associated with miRNA or disease, overlooking the fact that the human body is a highly complex system where miRNA or disease may indirectly correlate with various types of biomolecules. To address this, we propose a novel prediction model named MHGTMDA (miRNA and disease association prediction using Heterogeneous Graph Transformer based on Molecular Heterogeneous Graph). MHGTMDA integrates biological entity relationships of eight biomolecules, constructing a relatively comprehensive heterogeneous biological entity graph. MHGTMDA serves as a powerful molecular heterogeneity map transformer, capturing structural elements and properties of miRNAs and diseases, revealing potential associations. In a 5-fold cross-validation study, MHGTMDA achieved an Area Under the Receiver Operating Characteristic Curve (AUC) of 0.9569, surpassing state-of-the-art methods by at least 3%. Feature ablation experiments suggest that considering features among multiple biomolecules is more effective in uncovering miRNA-disease correlations. Furthermore, we conducted differential expression analyses on breast cancer and lung cancer, using MHGTMDA to further validate differentially expressed miRNAs. The results demonstrate MHGTMDA’s capability to identify novel MDAs. MHGTMDA is free and available at https://github.com/zht-code/HGTMDA.git.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
MHGTMDA:基于生物实体图的分子异质图转换器,用于 miRNA 与疾病的关联预测
微RNA(miRNA)在复杂疾病的预防、预后、诊断和治疗中发挥着至关重要的作用。现有的计算方法主要关注与 miRNA 或疾病直接相关的生物相关分子,而忽略了人体是一个高度复杂的系统,miRNA 或疾病可能与各种类型的生物大分子间接相关。针对这一问题,我们提出了一种名为 MHGTMDA(使用基于分子异质图的异质图转换器进行 miRNA 与疾病关联预测)的新型预测模型。MHGTMDA 整合了八种生物分子的生物实体关系,构建了一个相对全面的异质生物实体图。MHGTMDA 是一个功能强大的分子异质图转换器,它能捕捉 miRNA 与疾病的结构元素和属性,揭示潜在的关联。在一项 5 倍交叉验证研究中,MHGTMDA 的接收者工作特征曲线下面积(AUC)达到了 0.9569,比最先进的方法至少高出 3%。特征消减实验表明,考虑多种生物大分子的特征更能有效地发现 miRNA 与疾病的相关性。此外,我们还利用 MHGTMDA 对乳腺癌和肺癌进行了差异表达分析,以进一步验证差异表达的 miRNA。这些结果证明了 MHGTMDA 识别新型 MDA 的能力。MHGTMDA 可在 https://github.com/zht-code/HGTMDA.git 免费获取。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
15.40
自引率
1.10%
发文量
336
审稿时长
20 weeks
期刊介绍: Molecular Therapy Nucleic Acids is an international, open-access journal that publishes high-quality research in nucleic-acid-based therapeutics to treat and correct genetic and acquired diseases. It is the official journal of the American Society of Gene & Cell Therapy and is built upon the success of Molecular Therapy. The journal focuses on gene- and oligonucleotide-based therapies and publishes peer-reviewed research, reviews, and commentaries. Its impact factor for 2022 is 8.8. The subject areas covered include the development of therapeutics based on nucleic acids and their derivatives, vector development for RNA-based therapeutics delivery, utilization of gene-modifying agents like Zn finger nucleases and triplex-forming oligonucleotides, pre-clinical target validation, safety and efficacy studies, and clinical trials.
期刊最新文献
Allele-specific CRISPR-Cas9 editing inactivates a single-nucleotide variant associated with collagen VI muscular dystrophy. CRISPR-Cas13d: RNA's own Jedi Master in the fight against viral darkness. Boosting CRISPR-Cas9 efficiency through enhanced homologous recombination. Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS Quality by design for mRNA platform purification based on continuous oligo-dT chromatography
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1